Research programme: neprilysin inhibitors - Innoviva

Drug Profile

Research programme: neprilysin inhibitors - Innoviva

Alternative Names: Angiotensin receptor-neprilysin inhibitor programme; ARNI programme; TBPH NEPi

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Theravance
  • Developer Innoviva
  • Class
  • Mechanism of Action Neprilysin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute heart failure; Chronic heart failure; Renal failure
  • No development reported Hypertension

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Hypertension in USA
  • 13 Oct 2015 Theravance Biopharma files an IND application with the FDA for a phase I trial in Healty volunteers
  • 10 Aug 2015 Preclinical trials in Acute heart failure (Monotherapy) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top